Program
clazakizumab
Also written as “BMS-945429”, “ALD518” and “Clazakizumab”.
Its studies are mostly in Arthritis, Rheumatoid · Atherosclerosis · Crohn Disease · Arthritis, Psoriatic · Stomatitis, led by 2 companies.
Drug pageClazakizumab: every studyAll 19 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| CSLits history only | 90 open or running | phase 3since Nov 6, 2018 | Mar 20, 2009 | none ahead |
| Eli Lilly | 11 open or running | phase 2since Aug 21, 2026 | Aug 21, 2026 | May 2027phase 2 · NCT07783802 |
- Named in Eli Lilly’s own pipeline as
Clazakizumab
, phase 2, as of Oct 29, 2026 (source).
Also a collaborator on its studies: ICON Clinical Research.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Eli Lilly only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Aug 21, 2026First study: phase 2 study in AtherosclerosisFirst studyNCT07783802 · 120 planned · United States, Argentina, Japan and more
Ahead
- May 2027Primary completion: phase 2 study in AtherosclerosisNCT07783802
TargetBeta
“A humanized monoclonal antibody directed against the pro-inflammatory cytokine interleukin-6 (Il-6) with potential immunomodulating activity. Upon administration, clazakizumab binds to and blocks the activity of IL-6, which may mitigate the catabolic effects of IL-6.”NCIt, read by Claude
“Interleukin-6 inhibitor”ChEMBL 37, by rule
Other programs on IL6
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| olokizumabrule | R-Pharm | phase 3 | 19 |
| ziltivekimabrule | Novo Nordisk | phase 3 | 12 |
| pacibekitugrule | Novartis | phase 3 | 1 |
| isomyosaminerule | tnf-pharmaceuticals-inc | phase 2 | 1 |
Studies
The one study Eli Lilly leads. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07783802Atherosclerosis · United States, Argentina, Japan and more | 2 | Recruiting | May 2027 | 120 |
How it is read
Names in the registry
- “BMS-945429”, 16 entries
- “ALD518”, 8 entries
- “Clazakizumab”, 3 entries
Conditions, from the studies’ own filings
- Arthritis, Rheumatoid, 3 studies
- Atherosclerosis, 1 study
- Crohn Disease, 1 study
- Arthritis, Psoriatic, 1 study
- Stomatitis, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.